Arcturus Therapeutics Holdings Inc (ARCT)

NASD · Healthcare · Biotechnology · USA

Arcturus Therapeutics Holdings Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Arcturus Therapeutics Holdings develops messenger RNA medicines for rare liver and respiratory diseases. The company has clinical programs targeting ornithine transcarbamylase deficiency and cystic fibrosis, and partners with CSL Seqirus to commercialize KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine with regulatory approval across multiple jurisdictions. Arcturus leverages proprietary LUNAR delivery and STARR platform technologies.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Arcturus Therapeutics Holdings Inc stock.

Our verdict on ARCT

Overvalued: intrinsic value $6.39 per share, market price $7.97, margin of safety -24.7% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.39; the price of $7.97 is 25% above that value.

ETFs with the most weight in ARCT

17 more funds hold it; the full list is part of the paid plan.

More on ARCT

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ARCT in Biotechnology

31 more in this industry show a wider margin of safety.

Is ARCT undervalued or overvalued?

ARCT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.39; the price of $7.97 is 25% above that value.

What is the intrinsic value of ARCT?

$6.39 per share (as of the 2026-11-17 close), against a market price of $7.97. That is a margin of safety of -24.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.